N4P Stock Overview
N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
N4 Pharma Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.0067 |
52 Week High | UK£0.023 |
52 Week Low | UK£0.006 |
Beta | -0.065 |
1 Month Change | -10.00% |
3 Month Change | -25.00% |
1 Year Change | -59.09% |
3 Year Change | -91.56% |
5 Year Change | -90.36% |
Change since IPO | -89.41% |
Recent News & Updates
Recent updates
Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth
Oct 11Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation
Jul 06Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?
Mar 18Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay
Mar 01Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth
Dec 07Shareholder Returns
N4P | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | -6.9% | 4.8% | 2.3% |
1Y | -59.1% | 2.5% | 2.7% |
Return vs Industry: N4P underperformed the UK Pharmaceuticals industry which returned 0.6% over the past year.
Return vs Market: N4P underperformed the UK Market which returned 3.7% over the past year.
Price Volatility
N4P volatility | |
---|---|
N4P Average Weekly Movement | 16.2% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: N4P's share price has been volatile over the past 3 months.
Volatility Over Time: N4P's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1979 | 5 | Nigel Theobald | https://www.n4pharma.com |
N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
N4 Pharma Plc Fundamentals Summary
N4P fundamental statistics | |
---|---|
Market cap | UK£1.81m |
Earnings (TTM) | -UK£925.31k |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs N4P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
N4P income statement (TTM) | |
---|---|
Revenue | UK£0 |
Cost of Revenue | UK£0 |
Gross Profit | UK£0 |
Other Expenses | UK£925.31k |
Earnings | -UK£925.31k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0034 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did N4P perform over the long term?
See historical performance and comparison